Antibody Discovery: Services and Platforms, 2017-2027
The rising demand of personalized medicines to provide targeted treatment options has encouraged pharmaceutical companies to shift their focus from small molecules to discovery and development of biologics, particularly antibody based therapeutics. Antibodies, because of several advantages such as high specificity and targeted approach, are increasingly becoming crucial for the treatment of a number of diseases. In fact, since 2015, more than 20 antibodies have been approved by the USFDA. The growing popularity of antibody based therapeutics is also reflected from the dominance of these biologics in the portfolios of major biopharmaceutical companies.
At present, the focus of majority of biopharmaceutical companies is on discovering therapeutic antibodies against novel targets. However, discovery of antibodies is a long, arduous and costly process; as a result, there is a growing preference to outsource such operations. Drug developers are partnering with contract research organizations (CROs) that provide antibody discovery services using novel and advanced technologies. Outsourcing enables biopharmaceutical companies / academic institutes accelerate their drug discovery process by leveraging the technical capabilities and expertise of CROs. Additionally, a number of drug developers and academic institutes have obtained rights to access novel antibody discovery platforms from technology providers. As the demand of novel therapeutic antibodies for various disease areas is expected to rise steadily, we are optimistic about the future of the contract research firms that are driving innovation in the drug discovery process.
SCOPE OF THE REPORT
The ‘Antibody Discovery: Services and Platforms, 2017-2027’ report provides an extensive study on the current market landscape and future outlook of the antibody discovery service and platform providers. The study presents an in-depth analysis of a diverse set of companies that provide antibody discovery services and / or provide access to their platforms to drug developers. In addition to other elements, the report provides information on the following:
The competitive market landscape and industry analysis with respect to key players along with information on their geographical location, type of business operation, methods used for antibody generation and the purpose of antibody discovery (therapeutic and / or diagnostic).
Elaborate profiles of established / emerging players that offer a wide range of services in the overall antibody discovery process; each profile includes a brief overview of the company, information on its financial and funding details (if available), antibody discovery service portfolio and novel antibody discovery technology / platforms, and a view on its future outlook and strategy.
Most active regions in terms of antibody discovery services and platforms; the report contains schematic representations of world maps that clearly indicate the location of antibody discovery service hubs.
Platform competitiveness and supplier power (in the form of 2 X 2 matrices) across the growing landscape of antibody discovery platforms that are available for licensing.
A case study covering detailed information on the historical background of drug discovery process of some of the blockbuster therapeutic monoclonal antibodies such as Humira®, Remicade®, Herceptin®, Lucentis® and Simponi®.
Partnerships that have taken place in the recent past covering research collaborations, service agreements, license agreements, mergers / acquisitions and other deals signed between industry / non-industry stakeholders.
The study features a detailed analysis of the existing size and potential future growth opportunities (2017-2027) in the antibody discovery services market. We have provided insights on the likely evolution of the market in different regions including North America, Europe, China and rest of the world. In addition, we have provided the likely evolution on the basis of the steps involved in antibody discovery (antigen designing, hit generation, lead selection, lead optimization and lead characterization), antibody discovery methods (phage display, hybridoma, transgenic animal based, yeast display, single cell based and others), and the nature of antibody generated (chimeric, humanized and fully human). In order to account for the uncertainties associated with some of the key parameters and to add robustness to our model, we have presented three different forecast scenarios, depicting conservative, base and optimistic tracks of the market’s evolution.
The research, analysis and insights presented in this report are backed by a deep understanding of key insights gathered from both secondary and primary research. Actual figures have been sourced and analyzed from publicly available data. For the purpose of the study, we invited over 60 stakeholders to participate in a survey to solicit their opinions on upcoming opportunities, challenges and likely future trends. The opinions and insights presented in this study were also influenced by discussions conducted with experts in this field. These include contributions from Aaron Sato (Chief Scientific Officer, LakePharma), Debra Valsamis (Business Development Associate, Antibody Solutions), Christel Iffland (Vice President, Ligand Pharmaceuticals), Ignacio Pino (President and CEO, CDI Laboratories), Jeng Her (CEO, AP Biosciences) and Thomas Schirrmann (CEO and General Manager, YUMAB).
1. During the course of our study, we identified more than 60 companies that offer antibody discovery services. Majority (more than 80%) of these antibody discovery service providers are located in North America and EU. Examples of the players based in these regions include (in alphabetical order) Adimab, Aragen Bioscience, Antibody Solutions, Evotec, GenScript, Integral Molecular, ModiQuest Research and PX'Therapeutics.
2. It is worth highlighting that a number of start-ups have entered this domain to provide contract research services; examples include (in alphabetical order) Ab Studio, Abveris Antibody, AffinityImmuno, ChemBio Discovery Solutions, G&P Biosciences, HiFiBiO, OriMAbs, Panoply Bio and Specifica.
3. CROs offer antibody discovery services by deploying a variety of methods such as library based (phage display, yeast display and mammalian display), hybridoma, transgenic animal based and single cell based methods. During our research, we observed that a vast majority of companies (31) offer antibody discovery services by using library based methods. This is followed by companies that use hybridoma method (27), single cell based methods (13) and transgenic animal based methods (11).
4. Companies that have developed novel antibody drug discovery platforms are providing access / non-exclusive licenses of their proprietary platforms to drug developers, CROs and academic institutes. During the course of our study, we identified more than 20 such platform providers. Around 40% of the antibody discovery platform providers are headquartered in North America, 36% of companies are based in Europe while the remaining (24%) are located in the Asia Pacific region.
5. Majority (13) of the platforms available for licensing are library based; examples include Abtracer™, ADAPT™, ADLib® library, mAbLogix™ and n-CoDeR® antibody library. There are seven transgenic animal based platforms that are available for licensing; these include AlivaMab™ Mouse, Kymouse™ platform, OmniAb® platforms and TRIANNI Mouse platform.
6. A number of stakeholders in the field of antibody discovery have entered into collaborations with CROs and / or technology providers. We came across 172 deals that have been signed during the period 2011-2017. Majority (~50%) of the partnerships in this domain are research collaborations; this highlights the fact that extensive research is being conducted to discover novel therapeutic antibodies. Technology licensing is the second most popular partnership model in this field, capturing 32% share. Prominent contract service providers that have entered into multiple partnerships include Adimab, Crystal Biosciences, MAB Discovery, AbCellera and Abzena.
7. Driven by the rising demand for targeted therapies and innovation in antibody discovery methods, we expect the antibody discovery services market to witness continuous growth in the coming decade. In terms of geography, majority (more than 70%) of the share is distributed between North America and Europe; we believe that China is likely to grow at faster rate (annualized rate of 8.9%) as compared to other regions in the coming decade. With respect to antibody discovery methods, we believe that transgenic animal based method is likely to grow at a faster rate (annualized rate of 6.6%) as compared to the established methods such as phage display and hybridoma methods.
The data presented in this report has been gathered via secondary and primary research. For all our projects, we conduct interviews with experts in the area (academia, industry, medical practice and other associations) to solicit their opinions on emerging trends in the market. This is primarily useful for us to draw out our own opinion on how the market will evolve across different regions and type of biopharmaceuticals. Where possible, the available data has been checked for accuracy from multiple sources of information.
The secondary sources of information include:
News releases from company websites
Government policy documents
Industry analysts’ views
While the focus has been on forecasting the market over the coming ten years, the report also provides our view on various technological and non-commercial trends emerging in the industry. This opinion is solely based on our knowledge, research and understanding of the relevant market gathered from various secondary and primary sources of information.
Chapter 2 provides an executive summary of the insights captured in our research. The summary offers a high level view on the current state of the antibody discovery services and platforms market and its likely evolution in the mid-long term.
Chapter 3 provides a general overview of antibodies with information on their historical background, structure, isotypes, mechanism of action and applications. It also provides details on the different types of antibodies, such as polyclonal, monoclonal and bispecific antibodies.
Chapter 4 features information on the antibody discovery process and the various antibody discovery methods. It also includes a comparison of the different antibody discovery methods that are available currently. Additionally, the chapter provides insights on the gradual shift in development trends for monoclonal antibodies over the last three decades, from fully murine to fully human variants.
Chapter 5 includes a comprehensive landscape of the companies that offer antibody discovery services and / or provide licenses to their antibody discovery platforms. For the antibody discovery service providers, the chapter includes analyses on the basis of their geographical location, type of business operations, methods used for antibody generation, steps involved in antibody discovery and purpose of antibody discovery (therapeutic and / or diagnostic). For antibody discovery platform providers, the chapter provides analysis based on geographical location and antibody generation methods on which the platforms are based. Additionally, it contains a list of companies that have developed proprietary antibody discovery platforms / technologies to cater to their in-house discovery needs.
Chapter 6 provides detailed profiles of some of the players, based in different geographies, which are actively providing antibody discovery services to biopharmaceutical companies. Each company profile includes a brief overview of the company, its financial and funding information (if available), details on antibody discovery services and novel antibody discovery technology / platforms, and a view on its future outlook and strategy.
Chapter 7 provides detailed profiles of some of the important players, based in different geographies, which are actively providing access / licenses to their antibody discovery technology / platform to biopharmaceutical companies. Each company profile includes a brief overview of the company, funding instances, financial information (if available), details on antibody discovery technology / platforms and a view on its future outlook and strategy. The chapter also presents 2 X 2 matrices, comparing competitiveness and supplier power of the antibody discovery platforms.
Chapter 8 presents a comprehensive view on how the antibody discovery services market is likely to grow over the next ten years. We have segregated the financial opportunity on the basis of different regions (North America, Europe, China and rest of the world), the steps involved in antibody discovery (antigen designing, hit generation, lead selection, lead optimization and lead characterization), antibody discovery methods (phage display, hybridoma, transgenic animal based, yeast display, single cell based and others), and the nature of antibody generated (murine, chimeric, humanized and fully human). All our predictions are backed by robust analysis of data procured from both secondary and primary sources. The chapter also presents insightful 2 X 2 matrices to highlight the market share and market attractiveness derived from the current and likely future state of the market. Due to uncertainties surrounding some of the assumptions within our forecast model, we have presented three different growth tracks outlined as the conservative, base and optimistic scenarios.
Chapter 9 features an elaborate discussion and analysis on the collaborations and partnerships that have been inked amongst players in this market. We have also discussed the various partnership models that have been implemented, highlighting the most common forms of deals / agreements in this segment of the overall market.
Chapter 10 provides detailed information on the historical background of drug discovery process of some of the blockbuster therapeutic monoclonal antibodies. The antibodies for which details on discovery process and method are provided include Humira®, Remicade®, Herceptin®, Lucentis® and Simponi®.
Chapter 11 presents insights from the survey conducted for this study. We invited over 60 stakeholders involved in providing antibody discovery services and platforms. The participants, who were primarily Directors / CXO level representatives of their respective companies, helped us develop a deeper understanding on the nature of their services and the associated commercial potential.
Chapter 12 summarizes the overall report. It presents a list of key takeaways and offers our independent opinion on the current market scenario and evolutionary trends that are likely to determine the future of this market in the short and long term.
Chapter 13 is a collection of interview transcripts of our discussions with some of the key players in this industry. We have presented the details of our conversations with Aaron Sato (Chief Scientific Officer, LakePharma), Debra Valsamis (Business Development Associate, Antibody Solutions), Christel Iffland (Vice President, Ligand Pharmaceuticals), Ignacio Pino (President and CEO, CDI Laboratories), Jeng Her (CEO, AP Biosciences) and Thomas Schirrmann (CEO and General Manager, YUMAB).
Chapters 14 is an appendix, which provides tabulated data and numbers for all the figures in the report.
Chapter 15 is an appendix, which contains the list of companies and organizations that have been mentioned in the report.
LIST OF COMPANIES AND ORGANIZATIONS
The following companies and organizations have been mentioned in the report.
2. ABBA Therapeutics
3. AbGenics Life Sciences
5. AB Biosciences
6. Abbott Laboratories
14. Ab Studio
15. Abveris Antibody
16. Abwiz Bio
18. Abzyme Therapeutics
19. Accurus Biosciences
20. Acceleron Pharma
22. ACYTE Biotech
24. Aduro Biotech
25. Advantech Capital
29. Agilent Technologies
30. Aguettant Pharmaceutical
31. AIMM Therapeutics
32. Akeso Biopharma
35. Alder BioPharmaceuticals
38. Alexion Pharmaceuticals
45. Antibody Solutions
46. AP Biosciences
48. Aragen Bioscience
50. Aridis Pharmaceuticals
51. Aristi Biotech
57. BASF Bioresearch Corporation
58. Baylor Scott & White Research Institute
59. Bayer Pharma
60. Bill & Melinda Gates Foundation
66. BioRap Technologies
69. Bird Rock Bio
70. bluebird bio
71. Boehringer Ingelheim
72. Boston Children's Hospital
73. Brigham and Women’s Hospital
74. Bristol-Myers Squibb
75. Cambridge Antibody Technology
76. Cancer Research Technology
77. CDI Laboratories
80. Centers for Disease Control and Prevention
81. Centocor Biotech
82. Charles River Laboratories
83. ChemBio Discovery Solutions
85. Chiome Bioscience
86. Chugai Pharmaceutical
87. Chugai Pharmabody Research
88. CIS Bio
89. Commerce Health Capital
90. Compass Therapeutics
95. Cosmo Pharmaceuticals
96. Creative Biolabs
98. Crescendo Biologics
99. Cresset Biomolecular Discovery
101. Crystal Biosciences
103. Daiichi Sankyo
105. Defense Threat Reduction Agency (DTRA)
106. DJS Antibodies
107. Digital Proteomics
108. Distributed Bio
111. Eight Roads Ventures
113. Eli Lilly
114. Elusys Therapeutics
115. Emergent BioSolutions
117. Epimab Biotherapeutics
118. Erasmus University Medical Center
119. Essex Bio
120. Eureka Therapeutics
124. FairJourney Biologics
125. Five Prime Therapeutics
126. Fred Hutchinson Cancer Research Center
127. French Institute of Health and Medical Research (INSERM)
129. Fusion Antibodies
130. G&P Biosciences
131. GeneFrontier Corporation
134. Genor Biopharma
137. Georgia Institute of Technology
139. Gilead Sciences
141. Grenoble Hospital
142. GVK BIO
143. Harbour Antibodies
144. Harbour BioMed
145. HD Biosciences
146. Henlix Biotech
148. Heptares Therapeutics
149. HiFiBiO - High Fidelity Biology
151. HQL Pharmaceuticals
152. HUMABS BioMed
153. Human Genome Sciences
154. Ibex Biosciences
156. Igenica Biotherapeutics
157. ImClone Systems
158. Immune Biosolutions
160. Immunomic Therapeutics
166. Innovent Biologics
167. Institute for Transplantation-Urology-Nephrology, Nantes, France
168. Institute of Immunology of the Centre de Recherche Public-Santé
169. Institut Pasteur
170. Integral Molecular
174. iTeos Therapeutics
175. Janssen Biotech
176. Jiangsu Hengrui Medicine
177. Johnson & Johnson
178. Johnson & Johnson Pharmaceutical Research & Development
180. Kite Pharma
181. Kodiak Sciences
184. Kyowa Hakko Kirin
186. LAMPIRE Biological Laboratories
187. Legend Capital
188. Leland Stanford Junior University
189. Leiden University Medical Center
190. Les Laboratoires Servier
191. Life Sciences Fund Amsterdam
192. Ligand Pharmaceuticals
193. Lille Regional University Hospital Centre
194. MAB Discovery
195. MabSpace Biosciences
196. MabVax Therapeutics
197. Magenta Therapeutics
198. Maine Biotechnology Services
199. Malin Corporation
201. Massachusetts General Hospital
202. Maverick Therapeutics
205. Meditope Biosciences
206. Memo Therapeutics
207. Memorial Sloan Kettering Cancer Center
208. Merck Serono
209. Mersana Therapeutics
211. Millennium Pharmaceuticals
213. Mitsubishi Tanabe Pharma Corporation
214. ModiQuest Group
215. ModiQuest Research
217. Molecular Templates
219. MSM Protein Technologies
220. Nantes Centre for Research in Transplantation and Immunology
221. National Cancer Institute
222. National Institute of Allergy and Infectious Diseases (NIAID)
223. National Institute on Drug Abuse
224. NB Health Laboratory
226. NeoRX Corporation
228. NewSpring Capital
229. New York University (NYU)
230. North Coast Biologics
233. Novo Nordisk
235. Olympic Protein Technologies
238. ONO PHARMACEUTICAL
239. Open Monoclonal Technology
240. Organon Teknica
241. ORI Healthcare Fund
244. Oxford Biotherapeutics
247. Palatin Technologies
248. Panoply Bio
250. Ping An Bank
252. Potenza Therapeutics
254. Paris Public Welfare Hospital
255. Public Investment Bank
258. Quanta BioDesign
259. Queen Mary University of London
261. Regeneron Pharmaceuticals
262. Research Corporation Technologies
263. Ribovax Biotechnologies
265. SAB Biotherapeutics
266. Sanofi Aventis
267. Sea Lane Biotechnologies
268. Seattle Genetics
269. Sevion Therapeutics
271. Shenogen Pharma
272. Shenzhen Hepalink Pharmaceutical
274. Single Cell Technology
275. Singapore Immunology Network
279. SISCAPA Assay Technologies
280. Sutro Biopharma
281. Surface Oncology
284. Synthetic Biologics
285. Synthon Biopharmaceuticals
287. Takeda Pharmaceutical
288. Tanabe Research Laboratories
291. Teva Respiratory
292. The Chemistry Research Solution (TCRS)
293. Theraclone Sciences
294. The Scripps Research Institute
295. The US Army Edgewood Chemical Biological Center
296. Tizona Therapeutics
298. Trellis Bioscience
300. Trieza Therapeutics
301. Tri-Institutional Therapeutics Discovery Institute
303. United Therapeutics
304. University of Alabama
305. University of Amsterdam
306. University of California, Los Angeles
307. University of Texas Health Science Center
308. University Institute of Hematology, Paris
309. University of Southampton
310. University of Texas MD Anderson Cancer Center
311. University of Turku
312. University of Westminster
314. Valeant Pharmaceuticals
315. Viva Biotech
316. Viventia Bio
317. Warburg Pincus
318. Warwick Effect Polymers
319. Wellcome Trust
320. Wellcome Trust Sanger Institute
321. Woodford Investment Management
322. Woodford Patient Capital
323. WuXi AppTec
324. WuXi Biologics
325. WuXi PharmaTech
328. XOMA Corporation
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.Download eBook